Tilarginine

Drug Profile

Tilarginine

Alternative Names: 546C88; ANO-1020; BW546C88; L-NMMA; N-Monomethyl-arginine; NMA; TAI

Latest Information Update: 03 Sep 2009

Price : $50

At a glance

  • Originator Cornell Research Foundation; M. D. Anderson Cancer Center
  • Developer Arginox Pharmaceuticals
  • Class Antihypotensives; Basic amino acids; Diamino amino acids; Small molecules; Vascular disorder therapies
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiogenic shock
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Cardiogenic shock; Hypotension; Kidney disorders; Rheumatoid arthritis; Septic shock; Transplant rejection

Most Recent Events

  • 11 Dec 2015 Biomarkers information updated
  • 17 Nov 2006 Discontinued - Phase-II for Hypotension in United Kingdom (unspecified route)
  • 17 Nov 2006 Discontinued - Preclinical for Transplant rejection in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top